|Articles|April 21, 2021

Immunosuppressed Children Not at Higher Risk for Severe COVID-19

Author(s)Killian Meara

High levels of anxiety among immunocompromised children and their guardians highlights the need to clearly define COVID-19 risk.

A recent study conducted by investigators from the University of Southampton has discovered that children with weakened immune systems do not seem to show a higher risk for developing a severe infection with COVID-19.

Results from the study were published in the journal BMJ Open.

"Whilst we cannot be certain of the prevalence of COVID-19 amongst the children who took part, because testing was only done when patients were admitted and these children were told to adhere to strict shielding measures, we can assume that any infections would have been mild cases since none of these high risk patients required hospital admissions,” Hans de Graaf, a lead author on the study said.

For the study, investigators conducted an observational study, which included 1,500 immunocompromised children, spanning a 16 week period during the first wave of the pandemic. The participants were considered immunocompromised if they needed to receive an annual influenza vaccination due to underlying conditions.

Either the parents, guardians or the children filled out a week questionnaire in which they reported any COVID-19 related symptoms, any COVID-19 test results and how the pandemic had impacted their life on a daily basis.

Findings from the study showed that half of the participants reported high levels of anxiety at the start of the study, which persisted even though there was a lack of severe symptoms.

The investigators believe that the study demonstrates screening early for COVID-19 will not be useful in cases where children may have frequent upper respiratory tract symptoms, as they are likely to be unrelated to COVID-19.

"This study was the first to observe the impact of the pandemic on children with compromised immune systems,” de Graaf said. “During the first wave of the pandemic, many may have been shielding so our results suggest that either the shielding measures were effective or that immunocompromised children are less affected by COVID-19 than adults, just like healthy children."


Related to this article

Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.